Aclaris Therapeutics ACRS Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $19.96M-18.8% | $24.57M-38.4% | $39.88M-11.9% | $45.28M+65.6% | ||
| $70.79M-20.5% | $89.02M+12.4% | $79.23M-54.0% | $172.29M+5.0% | ||
| $96.32M-23.5% | $125.95M-2.3% | $128.86M-44.4% | $231.55M+12.9% | ||
| $761K-24.5% | $1.01M-37.8% | $1.62M+47.4% | $1.1M-17.7% | ||
| $2.77M-9.6% | $3.07M-26.3% | $4.16M+52.2% | $2.73M-23.1% | ||
| $60.61M-32.9% | $90.3M+43.9% | $62.77M+413% | $12.24M-64.2% | ||
| $160.46M-27.2% | $220.33M+11.6% | $197.41M-22.5% | $254.6M+1.3% | ||
| $13.16M+181% | $4.69M-47.2% | $8.88M-14.2% | $10.35M+3.7% | ||
| $2.75M+2.6% | $2.68M+2.1% | $2.63M-69.8% | $8.7M-13.4% | ||
| $3.94M+1.4% | $3.89M— | —— | —— | ||
| $551K+14.6% | $481K+12.9% | $426K-37.7% | $684K-1.3% | ||
| $16.17M-19.3% | $20.04M— | —— | —— | ||
| $28.65M-9.3% | $31.6M+2.1% | $30.95M+41.1% | $21.94M-4.3% | ||
| $2.12M-18.6% | $2.6M-25.8% | $3.5M+55.3% | $2.25M-20.7% | ||
| $1.57M-64.7% | $4.44M+44.4% | $3.07M+95.8% | $1.57M-27.7% | ||
| $57.38M-11.4% | $64.77M+61.0% | $40.23M-29.4% | $56.98M+5.8% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| $1.07B+1.1% | $1.06B+14.0% | $928.08M+5.4% | $880.83M+11.1% | ||
| -$967.78M-7.2% | -$902.86M-17.1% | -$770.8M-13.0% | -$682.32M-14.6% | ||
| $610K+529% | $97K+192% | -$106K+88.2% | -$897K-300% | ||
| $103.08M-33.7% | $155.55M-1.0% | $157.18M-20.5% | $197.62M+0.1% | ||
| $160.46M-27.2% | $220.33M+11.6% | $197.41M-22.5% | $254.6M+1.3% | ||
| $5.57M-55.0% | $12.36M— | —— | —— | ||
| $70.79M-20.5% | $89.02M+12.4% | $79.23M-54.0% | $172.29M+5.0% | ||
| $2.77M-9.6% | $3.07M-26.3% | $4.16M+52.2% | $2.73M-23.1% | ||
| $60.61M-32.9% | $90.3M+43.9% | $62.77M+413% | $12.24M-64.2% | ||
| $2.77M-9.6% | $3.07M-26.3% | $4.16M+52.2% | $2.73M-23.1% | ||
| $2.77M-9.6% | $3.07M-26.3% | $4.16M+52.2% | $2.73M-23.1% | ||
| $16.17M-19.3% | $20.04M— | —— | —— | ||
| $8.79M-56.8% | $20.33M+4.6% | $19.45M+123% | $8.7M-13.4% | ||
| $8.79M-56.8% | $20.33M+4.6% | $19.45M+123% | $8.7M-13.4% | ||
| $2.75M+2.6% | $2.68M+2.1% | $2.63M— | —— | ||
| $11M+26.4% | $8.7M+40.3% | $6.2M-81.3% | $33.1M+16.5% | ||
| $16.17M-19.3% | $20.04M— | —— | —— | ||
| $16.17M-19.3% | $20.04M— | —— | —— | ||
| $2.12M-18.6% | $2.6M-25.8% | $3.5M+55.3% | $2.25M-20.7% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Aclaris Therapeutics's total assets?
- Aclaris Therapeutics (ACRS) holds $198.7M in total assets, up 0.3% year over year.
- How much debt does Aclaris Therapeutics have?
- Aclaris Therapeutics carries $2.0M in total debt against $143.6M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Aclaris Therapeutics have?
- Aclaris Therapeutics holds $28.7M in cash and equivalents.
- Can Aclaris Therapeutics cover its short-term obligations?
- Its current ratio is 4.03 — current assets exceed current liabilities.
- Where does Aclaris Therapeutics's balance sheet data come from?
- Every line is extracted from Aclaris Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
